top of page
About us
CEO Greetings
Company Overview
History
Investors
Technology
Stem Cell Exosome Therapeutics
Exosome Platform
Plant Exosome
Anti-cancer Drug
Pipeline
Achievement
Patent
Paper
Communication
Notice
News
Contact
Communication
Announcement
News
All Posts
Disclosure
Notice
News
Nov 20, 2022
Prof. Jae-Hyung Park and Dong-kyu Cho selected as regular members of KAST
Sep 27, 2022
The 'stem cell' challenge continues in the 'osteoarthritis' treatment market
Apr 21, 2022
Exostemtech applied for phase 1 clinical trial IND in Korea for an exosome-based osteoarthritis trea
Jan 6, 2022
Daewoong Pharmaceutical and ExostemTech, joint development agreement for exosome treatment
Nov 19, 2021
[Jump-Up Bio] Exostemtech said, "The first clinical trial in Korea next year...He's even going to ge
Nov 14, 2021
"The strength of Exostemtech is…World-class exosome mass production, analysis, and quality managemen
Oct 26, 2021
Exostemtech, a "exosome treatment," attracts 10 billion won in series B investment (Korea economy)
Jul 19, 2021
Exostemtech, Cancer Exosome Inhibitor Clinical Full-scale (The Bell)
Jul 16, 2021
Exostemtech approved phase 1 and 2a clinical trials for combination of Kitruda and Exosome inhibitor
bottom of page
